Summary: the aim of the study was to assess the overall survival (OS) rates depending on the type of radiation therapy as well as method-specific survival rates depending on the biological subtype of breast cancer. In the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, from 2012 to 2020, 60 patients with brain metastasis of breast cancer were given radiation therapy. The median age was 51.7±10.82 years. Patients with stages II and III prevailed. Among biological subtypes, HER2 positive non-luminal and triple negative variants were the most common. The average time to progression was 30 months. Whole brain irradiation was given to 39 patients. Fractional stereotactic radiation therapy (FSRT) was performed on 21 patients. With a median follow-up of 61 months, overall survival was 39 months, regardless of the type of radiation therapy and biological subtype of breast cancer. Method-specific survival was 10 months. The OS was approximately 3 times higher in patients who received FSRT delivered to brain metastases compared to that observed in patients who received whole brain irradiation (19 months versus 7 months, respectively, p>0.05). The best treatment results were observed in patients with brain metastases of luminal B HER2 positive type: OS was 17 months, 1-year-old survival rate – 31 %. The most unfavorable in terms of response to treatment was triple negative cancer. Thus, the median OS after the treatment did not exceed 5 months, and the 1-year survival rate was 11 % (p>0.05).